MNZL - ETF AI Analysis
Top Page
Manzil Russell Halal USA Broad Market ETF (MNZL)
MNZL, the Manzil Russell Halal USA Broad Market ETF, has a solid overall rating, largely supported by heavyweight positions in leaders like Apple and Micron, which benefit from strong financial performance, bullish or supportive technical trends, and clear growth opportunities in areas like services, AI, and advanced memory. Additional strength comes from diversified holdings such as Merck, Johnson & Johnson, and Broadcom, which combine robust earnings and strategic initiatives, though some names like AbbVie and Procter & Gamble introduce risks related to financial stability, leverage, or weaker technical trends. The main risk factor is the fund’s meaningful concentration in a few large technology and healthcare names, which can increase volatility if those sectors or companies face setbacks.
MNZL vs. SPDR S&P 500 ETF (SPY)
- AUM
- 34.71M
- Region
- North America
- Expense Ratio
- 0.40%
- Beta
- 1.01
- Issuer
- Manzil
- Inception Date
- Nov 18, 2025
- Dividend Yield
- 0.03%
- Asset Class
- Equity
- Index Tracked
- Russell Ideal Ratings Manzil Halal USA Broad Market Custom Index - Benchmark TR Gross
MNZL Summary
MNZL, the Manzil Russell Halal USA Broad Market ETF, follows the Russell Ideal Ratings Manzil Halal USA Broad Market Custom Index, focusing on large U.S. companies that meet Islamic ethical (Shariah) standards. It mainly invests in technology and health care, with well-known holdings like Apple and Tesla, giving investors exposure to many leading American businesses in a single fund. Someone might invest in MNZL for broad diversification and potential long-term growth while staying aligned with religious or ethical values. A key risk is that it is heavily tilted toward tech stocks, so its price can rise and fall sharply with that sector and the overall market.
How much will it cost me?
The Manzil Russell Halal USA Broad Market ETF (MNZL) has an expense ratio of 0.4%, which means you’ll pay $4 per year for every $1,000 invested. This is higher than average because it is actively managed to ensure compliance with Shariah principles, requiring additional oversight and specialized criteria.
What would affect this ETF?
The MNZL ETF, heavily focused on technology and healthcare sectors, could benefit from continued innovation and growth in these industries, especially if consumer demand for tech products and advancements in healthcare remain strong. However, it may face challenges from rising interest rates, which can negatively impact growth stocks like those in the tech sector, or economic slowdowns that reduce consumer spending in cyclical industries. Additionally, regulatory changes affecting Shariah-compliant investments or large-cap companies could influence its performance.
MNZL Top 10 Holdings
This halal U.S. large-cap ETF is heavily powered by tech, with Apple and a trio of chip names—Micron, AMD, and Broadcom—doing most of the heavy lifting. Micron and AMD have been rising sharply, giving the fund a strong AI-and-semiconductors flavor, while Broadcom’s more mixed showing keeps some of that momentum in check. Tesla adds a splash of consumer cyclical flair but has been dragging performance lately. Health care names like Eli Lilly provide a steadier counterweight, helping balance out the tech-driven, U.S.-only growth story.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 AAPL | Apple | 16.67% | $5.79M | $5.01T | 38.80% | 79Outperform |
 AVGO | Broadcom | 5.40% | $1.87M | $1.57T | -7.17% | 76Outperform |
 TSLA | Tesla | 3.56% | $1.24M | $1.40T | -17.27% | 73Outperform |
 MU | Micron | 3.54% | $1.23M | $994.34B | 333.93% | 79Outperform |
 LLY | Eli Lilly & Co | 3.36% | $1.17M | $1.18T | 53.41% | 72Outperform |
 AMD | Advanced Micro Devices | 3.08% | $1.07M | $863.17B | 125.42% | 73Outperform |
 JNJ | Johnson & Johnson | 2.06% | $713.49K | $615.87B | 33.02% | 78Outperform |
 ABBV | AbbVie | 1.69% | $586.64K | $504.37B | 25.81% | 66Neutral |
 PG | Procter & Gamble | 1.23% | $427.89K | $370.12B | 6.52% | 69Neutral |
 MRK | Merck & Company | 1.21% | $419.74K | $360.08B | 73.92% | 80Outperform |
MNZL Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MNZL, the sentiment is Negative. The current price of 60.01 is below the 20-day moving average (MA) of 61.36, below the 50-day MA of 60.71, and above the 200-day MA of 56.92, indicating a neutral trend. The MACD of 0.10 indicates Positive momentum. The RSI at 40.07 is Neutral, neither overbought nor oversold. The STOCH value of 10.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MNZL.
MNZL Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| MNZL | $60.01 | $67.00(11.66% Upside) | $34.71M | 0.40% | 73Outperform |
 ACEP | $19.82 | $23.84(20.24% Upside) | $99.92M | 0.46% | 71Outperform |
 PRMR | $28.26 | $34.16(20.86% Upside) | $92.51M | 1.00% | 73Outperform |
 FCUS | $38.17 | $46.82(22.64% Upside) | $87.71M | 0.80% | 67Neutral |
 SPXE | $81.80 | $99.84(22.06% Upside) | $87.01M | 0.09% | 74Outperform |
 QARP | $68.99 | $79.50(15.22% Upside) | $79.68M | 0.19% | 73Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MNZL | Manzil Russell Halal USA Broad Market ETF | 60.01 | 9.88 | 19.70% | |
| ACEP | ARS Core Equity Portfolio ETF | 19.82 | 4.72 | 31.23% | |
| PRMR | PeakShares RMR Prime Equity ETF | 28.26 | 3.28 | 13.13% | |
| FCUS | Pinnacle Focused Opportunities ETF | 38.17 | 6.78 | 21.61% | |
| SPXE | ProShares S&P 500 Ex-Energy ETF | 81.80 | 9.73 | 13.49% | |
| QARP | Xtrackers Russell 1000 US Quality at a Reasonable Price ETF | 68.99 | 12.19 | 21.46% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.